These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19435924)

  • 1. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.
    Jäger M; Schoberth A; Ruf P; Hess J; Lindhofer H
    Cancer Res; 2009 May; 69(10):4270-6. PubMed ID: 19435924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling.
    Diermeier-Daucher S; Ortmann O; Buchholz S; Brockhoff G
    MAbs; 2012; 4(5):614-22. PubMed ID: 22820509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ertumaxomab: a trifunctional antibody for breast cancer treatment.
    Kiewe P; Thiel E
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1553-8. PubMed ID: 18808314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
    Kiewe P; Hasmüller S; Kahlert S; Heinrigs M; Rack B; Marmé A; Korfel A; Jäger M; Lindhofer H; Sommer H; Thiel E; Untch M
    Clin Cancer Res; 2006 May; 12(10):3085-91. PubMed ID: 16707606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.
    Haense N; Atmaca A; Pauligk C; Steinmetz K; Marmé F; Haag GM; Rieger M; Ottmann OG; Ruf P; Lindhofer H; Al-Batran SE
    BMC Cancer; 2016 Jul; 16():420. PubMed ID: 27387446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
    Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
    J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HER2: recent developments and future directions for breast cancer patients.
    Wang SC; Zhang L; Hortobagyi GN; Hung MC
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
    Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
    Baumann J; Wong J; Sun Y; Conklin DS
    BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
    Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
    J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.
    Suzuki E; Kataoka TR; Hirata M; Kawaguchi K; Nishie M; Haga H; Toi M
    BMC Cancer; 2015 Feb; 15():39. PubMed ID: 25655677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
    Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
    Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
    Verneris MR; Arshi A; Edinger M; Kornacker M; Natkunam Y; Karimi M; Cao YA; Marina N; Contag CH; Negrin RS
    Clin Cancer Res; 2005 Jun; 11(12):4561-70. PubMed ID: 15958642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
    Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
    J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.